Recursion Pharmaceuticals

Recursion Pharmaceuticals Goodwill

The Goodwill of Recursion Pharmaceuticals (RXRX) as of Nov 16, 2026 is 162.16 M USD. In the previous year, Goodwill was 148.87 M USD — a change of 8.92% (higher).

Goodwill

162.16 MUSD

YoY

8.92%

Last updated:

Goodwill of Recursion Pharmaceuticals is 2025 162.16 M USD. Goodwill of Recursion Pharmaceuticals was 2024 148.87 M USD. It decreases by 8.92% higher compared to the previous year.

The Recursion Pharmaceuticals Goodwill history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Goodwill
Date
Goodwill
Jan 1, 2020
801,000.00 USD
Jan 1, 2021
801,000.00 USD
Jan 1, 2022
801,000.00 USD
Jan 1, 2023
52.06 M USD
Jan 1, 2024
148.87 M USD
Jan 1, 2025
162.16 M USD
The Recursion Pharmaceuticals Goodwill history
YEARGoodwillYoY
162.16 MUSD+8.92%
148.87 MUSD+185.99%
52.06 MUSD+6,398.88%
801,000.00USD0.00%
801,000.00USD0.00%
801,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Recursion Pharmaceuticals Stock analysis

What does Recursion Pharmaceuticals do? Recursion Pharmaceuticals, Inc. makes money by developing novel therapeutics through its Recursion Operating System (OS), which integrates automation, artificial intelligence, machine learning, and in vivo validation. The company focuses on discovering medicines using advanced technologies in biology, chemistry, automation, and computer science. Its clinical programs include REC-994, REC-2282, REC-4881, and REC-3964, with REC-994 being an orally bioavailable, superoxide scavenger small molecule for treating cerebral cavernous malformations. The company generates revenue from its platform and clinical development efforts, targeting biopharmaceutical partnerships and potential future drug sales. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, leveraging its Recursion Data Universe to map biological and chemical relationships. The Recursion Operating System (OS) enables the company to rapidly translate silico hypotheses into validated insights and novel chemistry through iterative loops of wet lab biology and chemistry data. The company's platform integrates physical and digital components to create virtuous cycles, driving the discovery of novel therapeutics. Revenue is derived from its technology platform and clinical programs, with potential partnerships in the biopharmaceutical sector. The company's primary products are its Recursion Operating System (OS) and clinical programs such as REC-994, REC-2282, REC-4881, and REC-3964. REC-994 is a small molecule designed for cerebral cavernous malformations, while the other programs are part of its broader therapeutic pipeline. The company targets biopharmaceutical companies and research institutions as potential partners for its technology and drug development services. Recursion Pharmaceuticals, Inc. monetizes its platform through licensing agreements and collaborative research deals, focusing on the discovery of novel medicines using AI-driven approaches. Recursion Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Recursion Pharmaceuticals stock

Goodwill of Recursion Pharmaceuticals is 162.16 M USD in 2025.

Goodwill of Recursion Pharmaceuticals changed from 148.87 M USD to 162.16 M USD, representing a 8.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Goodwill Recursion Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Goodwill is the premium paid above fair market value in an acquisition. It represents intangible value such as brand recognition, customer relationships, and intellectual property.

Goodwill's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill's Recursion Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Recursion Pharmaceuticals

All Key Metrics — Recursion Pharmaceuticals